SpringWorks Therapeutics (SWTX) Set to Announce Earnings on Thursday

SpringWorks Therapeutics (NASDAQ:SWTX) is set to announce its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($1.19) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its earnings results on Tuesday, February 27th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($1.24) by ($0.20). The firm had revenue of $5.45 million during the quarter, compared to analyst estimates of $1.26 million. During the same period last year, the company posted ($1.19) earnings per share. On average, analysts expect SpringWorks Therapeutics to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

SpringWorks Therapeutics Price Performance

Shares of SWTX opened at $46.45 on Tuesday. The business’s 50-day moving average price is $47.49 and its 200 day moving average price is $38.13. SpringWorks Therapeutics has a 1-year low of $18.00 and a 1-year high of $53.92.

Insider Activity

In related news, insider Daniel Pichl sold 15,000 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $50.10, for a total transaction of $751,500.00. Following the completion of the sale, the insider now directly owns 45,212 shares in the company, valued at $2,265,121.20. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 7.61% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

SWTX has been the topic of several analyst reports. HC Wainwright lifted their target price on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Guggenheim initiated coverage on shares of SpringWorks Therapeutics in a research note on Monday, February 5th. They set a “buy” rating and a $75.00 target price on the stock. JPMorgan Chase & Co. raised their target price on SpringWorks Therapeutics from $73.00 to $74.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. Barclays lifted their price target on SpringWorks Therapeutics from $47.00 to $63.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Finally, Wedbush raised their price objective on SpringWorks Therapeutics from $60.00 to $70.00 and gave the stock an “outperform” rating in a research report on Monday, February 26th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $68.00.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.